Poly (lactic-co-glycolic acid) NPs conjugated with CD133 aptamers, specifically delivered salinomycin to CD133+ Saos-2 CSCs significantly attenuating osteosarcoma tumour growth in comparison to salinomycin-only treatment (7.1-fold increase in tumour growth over 60 days in comparison to 17.4-fold increase) as well as reducing the frequency of CD133+ cells in vivo [15]. Here, PROM1 is linked to neoplasm.